| Camptosar |
was approved as first-line therapy for the treatment of patients with metastatic colorectal cancer (advanced cancer that has spread beyond the colon or rectum) in combination with 5-fluorouracil/leucovorin (5-FU/LV). Camptosar is associated with myelosuppression and both early (during or shortly after infusion) and late (more than 24 hours after infusion) forms of diarrhea, that may be severe. ...
Ãâó: www.careerstep.com/newsletter/00aprmay/terminology...
|
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|